Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 16/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3832520 | 1.00 | SLC6A4 (0.37) | SLC6A4SLC6A2SLC6A3KCNH2NOS3 | |
| SCHEMBL13567753 | 1.00 | SLC6A4 (0.37) | SLC6A4SLC6A2SLC6A3KCNH2NOS3 | |
| SCHEMBL8442588 | 0.91 | SLC6A4 (0.38) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL1009314 | 0.87 | SLC6A2 (0.32) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| SCHEMBL2199790 | 0.85 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL2199793 | 0.85 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL2204531 | 0.85 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| Hydrochloric Acid SCHEMBL4796823 | 0.84 | HTR2C (0.31) | SLC6A4SLC6A2NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL16108942 | 0.84 | NOS2 (0.35) | NOS3NOS1NOS2CYP2D6 | |
| Hydrochloric Acid SCHEMBL16109201 | 0.84 | NOS2 (0.35) | NOS3NOS1NOS2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | SLC6A4 4784/4885SLC6A2 4884/4885SLC6A3 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.